Neogap Therapeutics appoints CMO
Dr Hanjing Xie brings over 25 years of experience from the pharmaceutical industry and university hospitals and institutes. She has worked at companies such as Idogen, Oncopeptides and Bayer, as well as Karolinska University Hospital, Karolinska Institute and St Göran's Hospital. Xie is an associate professor and senior consultant in oncology, holds a PhD in clinical pharmacology and has registrations in clinical oncology, internal medicine and haematology.
The new CMO will oversee Neogap's clinical development programmes and pipeline, and provide medical oversight of the company's first human trial. Swedish biotechnology company Neogap Therapeutics specialises in the development of personalised cancer immunotherapy using a patient's own cells. Recently, the company received CTA approval for a phase I/IIa clinical trial with its advanced cell therapy pTTL (personalised tumour-trained lymphocytes) against colorectal cancer. The phase I/IIa trial is expected to start in the first half of 2023. The therapy is based on the company's two technologies PIOR® and EpiTCer®.
Neogap Therapeutics is based at the Centre for Molecular Medicine at the Karolinska Institute in Stockholm.